Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Cervical Cancer | Research

Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer

Authors: Chunnian Zhang, Liqin Gu, Juan Xiao, Feng Jin

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

RNA binding motif protein 15 (RBM15), a writer of N6-methyladenosine (m6A) methylation, contributes significantly to the development of various tumors. However, the function of RBM15 in cervical cancer (CC) has not been determined.

Methods

Based on the GSE9750, GSE63514, and m6A datasets, m6A-related differentially expressed genes (DEGs) were screened out. The hub genes were identified by generating a Protein-Protein Interaction (PPI) network. RT-qPCR was conducted to assess the mRNA expression of hub genes. CCK8, scratch wound healing, and transwell assays were utilized to examine the influence of RBM15 on HeLa and SiHa cells. Tumor xenograft models were used to assess the effects of RBM15 on tumorigenesis. A mechanistic analysis of RBM15 in CC tumors was conducted using the GeneCards and Coxpresdb databases, followed by a Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, and the pathway-related genes were subsequently validated using Western blotting.

Results

Five DEGs were screened, including WTAP, RBM15, CBLL1, and YTHDC2. Among them, WTAP, RBM15, CBLL1, and YTHDC2 were hub genes and can be used as biomarkers for CC. RBM15 expression was considerably increased, while WTAP, CBLL1, and YTHDC2 were significantly downregulated. Knockdown of RBM15 significantly suppressed the proliferation, invasion, and migration of CC cells and tumorigenesis. Moreover, knockdown of RBM15 significantly reduced the expression levels of proteins related to the JAK-STAT pathway.

Conclusions

Knockdown of RBM15 inhibited the progression of CC cells, which probably by inhibiting the JAK-STAT pathway pathway.

Available only for authorised users

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca-Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Gupta SM, Mania-Pramanik J. Molecular mechanisms in progression of HPV-associated cervical carcinogenesis. J Biomed Sci. 2019;26(1):28. https://doi.org/10.1186/s12929-019-0520-2.CrossRefPubMedPubMedCentral

Plummer M, Peto J, Franceschi S, International Collaboration of Epidemiological Studies of Cervical C. Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer. 2012;130(11):2638–44. https://doi.org/10.1002/ijc.26250.CrossRefPubMed

Hoover DS, Spears CA, Vidrine DJ, Walker JL, Shih Y-CT, Wetter DW. Smoking Cessation Treatment needs of low SES Cervical Cancer Survivors. Am J Health Behav. 2019;43(3):606–20. https://doi.org/10.5993/ajhb.43.3.14.CrossRefPubMedPubMedCentral

Balasubramaniam SD, Balakrishnan V, Oon CE, Kaur G. Key molecular events in Cervical Cancer Development. Med (Kaunas). 2019;55(7). https://doi.org/10.3390/medicina55070384.

Jain A, Ganesh B, Bobdey SC, Sathwara JA, Saoba S. Sociodemographic and Clinical Profile of Cervical Cancer Patients visiting in a Tertiary Care Hospital in India. Indian J Med Paediatr Oncol. 2017;38(3):291–5. https://doi.org/10.4103/ijmpo.ijmpo_20_16.CrossRefPubMedPubMedCentral

Rosen VM, Guerra I, McCormack M, Nogueira-Rodrigues A, Sasse A, Munk VC, Shang A. Systematic review and network Meta-analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, recurrent, or metastatic cervical Cancer. Int J Gynecol Cancer. 2017;27(6):1237–46. https://doi.org/10.1097/IGC.0000000000001000.CrossRefPubMedPubMedCentral

Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971–5. https://doi.org/10.1073/pnas.71.10.3971.CrossRefPubMedPubMedCentral

Zhang H, Shi X, Huang T, Zhao X, Chen W, Gu N, Zhang R. Dynamic landscape and evolution of m6A methylation in human. Nucleic Acids Res. 2020;48(11):6251–64. https://doi.org/10.1093/nar/gkaa347.CrossRefPubMedPubMedCentral

10.

Garcias Morales D, Reyes JL. A birds’-eye view of the activity and specificity of themRNA m6Amethyltransferase complex. WIREs RNA. 2020;12(1). https://doi.org/10.1002/wrna.1618.

11.

Wang X, Tian L, Li Y, Wang J, Yan B, Yang L, Li Q, Zhao R, Liu M, Wang P, Sun Y. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. J Exp Clin Cancer Res. 2021;40(1):80. https://doi.org/10.1186/s13046-021-01871-4.CrossRefPubMedPubMedCentral

12.

Cai X, Chen Y, Man D, Yang B, Feng X, Zhang D, Chen J, Wu J. RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner. Cell Death Discov. 2021;7(1):315. https://doi.org/10.1038/s41420-021-00703-w.CrossRefPubMedPubMedCentral

13.

Zhang Z, Mei Y, Hou M. Knockdown RBM15 inhibits Colorectal Cancer Cell Proliferation and Metastasis Via N6-Methyladenosine (m6A) modification of MyD88 mRNA. Cancer Biother Radiopharm. 2022;37(10):976–86. https://doi.org/10.1089/cbr.2021.0226.CrossRefPubMed

14.

Darnell JE Jr. STATs and gene regulation. Science. 1997;277(5332):1630–5. https://doi.org/10.1126/science.277.5332.1630.CrossRefPubMed

15.

Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis. 2021;42(12):1411–9. https://doi.org/10.1093/carcin/bgab075.CrossRefPubMedPubMedCentral

16.

Jin W. Role of JAK/STAT3 signaling in the regulation of Metastasis, the transition of Cancer Stem cells, and Chemoresistance of Cancer by epithelial-mesenchymal transition. Cells. 2020;9(1). https://doi.org/10.3390/cells9010217.

17.

Gutierrez-Hoya A, Soto-Cruz I. Role of the JAK/STAT pathway in Cervical Cancer: its relationship with HPV E6/E7 oncoproteins. Cells. 2020;9(10). https://doi.org/10.3390/cells9102297.

18.

Chen X, He H, Xiao Y, Hasim A, Yuan J, Ye M, Li X, Hao Y, Guo X. CXCL10 produced by HPV-Positive cervical Cancer cells stimulates exosomal PDL1 expression by fibroblasts via CXCR3 and JAK-STAT pathways. Front Oncol. 2021;11:629350. https://doi.org/10.3389/fonc.2021.629350.CrossRefPubMedPubMedCentral

19.

Zhu X, Yang H, Zhang M, Wu X, Jiang L, Liu X, Lv K. YTHDC1-mediated VPS25 regulates cell cycle by targeting JAK-STAT signaling in human glioma cells. Cancer Cell Int. 2021;21(1):645. https://doi.org/10.1186/s12935-021-02304-0.CrossRefPubMedPubMedCentral

20.

Wu S, He G, Liu S, Cao Y, Geng C, Pan H. Identification and validation of the N6-methyladenosine RNA methylation regulator ZC3H13 as a novel prognostic marker and potential target for hepatocellular carcinoma. Int J Med Sci. 2022;19(4):618–30. https://doi.org/10.7150/ijms.69645.CrossRefPubMedPubMedCentral

21.

Han Q, Zhang X, Ren X, Hang Z, Yin Y, Wang Z, Chen H, Sun L, Tao J, Han Z, Tan R, Gu M, Ju X. Biological characteristics and predictive model of Biopsy-Proven Acute rejection (BPAR) after kidney transplantation: evidences of Multi-Omics Analysis. Front Genet. 2022;13:844709. https://doi.org/10.3389/fgene.2022.844709.CrossRefPubMedPubMedCentral

22.

Liu Y, Wang J, Li L, Qin H, Wei Y, Zhang X, Ren X, Ding W, Shen X, Li G, Lu Z, Zhang D, Qin C, Tao L, Chen X. AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma. Sci Rep. 2022;12(1):4272. https://doi.org/10.1038/s41598-022-07070-1.CrossRefPubMedPubMedCentral

23.

Jiang S, Ren X, Liu S, Lu Z, Xu A, Qin C, Wang Z. Integrated Analysis of the Prognosis-Associated RNA-Binding protein genes and candidate drugs in renal papillary cell carcinoma. Front Genet. 2021;12:627508. https://doi.org/10.3389/fgene.2021.627508.CrossRefPubMedPubMedCentral

24.

Zhang D, Xu X, Wei Y, Chen X, Li G, Lu Z, Zhang X, Ren X, Wang S, Qin CJCcjotMCC. (2022) Prognostic role of DNA damage response genes mutations and their Association with the sensitivity of olaparib in prostate Cancer patients. 29:10732748221129451. https://doi.org/10.1177/10732748221129451.

25.

Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. DAVID: database for annotation, visualization, and Integrated Discovery. Genome Biol. 2003;4(5):P3.CrossRefPubMed

26.

Pei J, Li M, Wu C, Xu M, Shu T, Zhu C. Worldwide trends in cervical cancer incidence and mortality. Cancer. 2022;128(5):1141. https://doi.org/10.1002/cncr.34029.CrossRefPubMed

27.

Ran Y, Yan Z, Jiang B, Liang P. N6-methyladenosine functions and its role in skin cancer. Exp Dermatol. 2023;32(1):4–12. https://doi.org/10.1111/exd.14696.CrossRefPubMed

28.

Lan T, Li H, Zhang D, Xu L, Liu H, Hao X, Yan X, Liao H, Chen X, Xie K, Li J, Liao M, Huang J, Yuan K, Zeng Y, Wu H. KIAA1429 contributes to liver cancer progression through N6-methyladenosine-dependent post-transcriptional modification of GATA3. Mol Cancer. 2019;18(1):186. https://doi.org/10.1186/s12943-019-1106-z.CrossRefPubMedPubMedCentral

29.

Liu T, Wei Q, Jin J, Luo Q, Liu Y, Yang Y, Cheng C, Li L, Pi J, Si Y, Xiao H, Li L, Rao S, Wang F, Yu J, Yu J, Zou D, Yi P. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48(7):3816–31. https://doi.org/10.1093/nar/gkaa048.CrossRefPubMedPubMedCentral

30.

Li R, Song Y, Chen X, Chu M, Wang ZW, Zhu X. METTL3 increases cisplatin chemosensitivity of cervical cancer cells via downregulation of the activity of RAGE. Mol Ther Oncolytics. 2021;22:245–55. https://doi.org/10.1016/j.omto.2021.05.013.CrossRefPubMedPubMedCentral

31.

Geng F, Fan MJ, Li J, Liang SM, Li CY, Li N. Knockdown of METTL14 inhibits the growth and invasion of cervical cancer. Transl Cancer Res. 2019;8(6):2307–15. https://doi.org/10.21037/tcr.2019.09.48.CrossRefPubMedPubMedCentral

32.

Wang H, Luo Q, Kang J, Wei Q, Yang Y, Yang D, Liu X, Liu T, Yi P. YTHDF1 aggravates the progression of Cervical Cancer through m(6)A-Mediated Up-Regulation of RANBP2. Front Oncol. 2021;11:650383. https://doi.org/10.3389/fonc.2021.650383.CrossRefPubMedPubMedCentral

33.

Condic M, Ralser DJ, Klumper N, Ellinger J, Qureischi M, Egger EK, Kristiansen G, Mustea A, Thiesler T. Comprehensive analysis of N6-Methyladenosine (m6A) Writers, Erasers, and readers in Cervical Cancer. Int J Mol Sci. 2022;23(13). https://doi.org/10.3390/ijms23137165.

34.

Zhang C, Guo C, Li Y, Ouyang L, Zhao Q, Liu K. The role of YTH domain containing 2 in epigenetic modification and immune infiltration of pan-cancer. J Cell Mol Med. 2021;25(18):8615–27. https://doi.org/10.1111/jcmm.16818.CrossRefPubMedPubMedCentral

35.

Hu M, Yang Y, Ji Z, Luo J. RBM15 Functions in Blood Diseases. Curr Cancer Drug Targets. 2016;16(7):579–85. https://doi.org/10.2174/1568009616666160112105706.CrossRefPubMed

36.

Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, Jaffrey SR. M(6)a RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369–73. https://doi.org/10.1038/nature19342.CrossRefPubMedPubMedCentral

37.

Torres L, Lisboa S, Vieira J, Cerveira N, Santos J, Pinheiro M, Correia C, Bizarro S, Almeida M, Teixeira MR. Acute megakaryoblastic leukemia with a four-way variant translocation originating the RBM15-MKL1 fusion gene. Pediatr Blood Cancer. 2011;56(5):846–9. https://doi.org/10.1002/pbc.22765.CrossRefPubMed

38.

Zeng X, Chen K, Li L, Tian J, Ruan W, Hu Z, Peng D, Chen Z. Epigenetic activation of RBM15 promotes clear cell renal cell carcinoma growth, metastasis and macrophage infiltration by regulating the m6A modification of CXCL11. Free Radic Biol Med. 2022;184:135–47. https://doi.org/10.1016/j.freeradbiomed.2022.03.031.CrossRefPubMed

39.

Yang F, Liu Y, Xiao J, Li B, Chen Y, Hu A, Zeng J, Liu Z, Liu H. Circ-CTNNB1 drives aerobic glycolysis and osteosarcoma progression via m6A modification through interacting with RBM15. Cell Prolif. 2023;56(1):e13344. https://doi.org/10.1111/cpr.13344.CrossRefPubMed

40.

Wang Q, Vattai A, Vilsmaier T, Kaltofen T, Steger A, Mayr D, Mahner S, Jeschke U, Hildegard Heidegger H. Immunogenomic Identification for Predicting the prognosis of Cervical Cancer Patients. Int J Mol Sci. 2021;22(5). https://doi.org/10.3390/ijms22052442.

41.

Morgan EL, Macdonald A. Manipulation of JAK/STAT signalling by high-risk HPVs: potential therapeutic targets for HPV-Associated Malignancies. Viruses. 2020;12(9). https://doi.org/10.3390/v12090977.

42.

Zheng X, Zhu Y, Wang X, Hou Y, Fang Y. Silencing of ITGB6 inhibits the progression of cervical carcinoma via regulating JAK/STAT3 signaling pathway. Ann Transl Med. 2021;9(9):803. https://doi.org/10.21037/atm-21-1669.CrossRefPubMedPubMedCentral

43.

Thakur K, Janjua D, Shishodia G, Chhokar A, Aggarwal N, Yadav J, Tripathi T, Chaudhary A, Senrung A, Bharti AC. Investigation of molecular mechanisms underlying JAK/STAT signaling pathway in HPV-induced cervical carcinogenesis using ‘omics’ approach. Med Oncol. 2022;39(12):255. https://doi.org/10.1007/s12032-022-01854-1.CrossRefPubMed

44.

Valentino L, Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol. 2006;71(6):713–21. https://doi.org/10.1016/j.bcp.2005.12.017.CrossRefPubMed

45.

Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens D, Deben C, Prenen H, Pauwels P, Trinh XB, Wouters A, Smits ELJ, Lardon F, van Dam PA. The potential and controversy of targeting STAT family members in cancer. Semin Cancer Biol. 2020;60:41–56. https://doi.org/10.1016/j.semcancer.2019.10.002.CrossRefPubMed

46.

Schindler C, Strehlow I. Cytokines and STAT signaling. Adv Pharmacol. 2000;47:113–74. https://doi.org/10.1016/s1054-3589(08)60111-8.CrossRefPubMed

47.

She S, Zhao Y, Kang B, Chen C, Chen X, Zhang X, Chen W, Dan S, Wang H, Wang YJ, Zhao J. Combined inhibition of JAK1/2 and DNMT1 by newly identified small-molecule compounds synergistically suppresses the survival and proliferation of cervical cancer cells. Cell Death Dis. 2020;11(9):724. https://doi.org/10.1038/s41419-020-02934-8.CrossRefPubMedPubMedCentral

48.

Polak KL, Chernosky NM, Smigiel JM, Tamagno I, Jackson MW. Balancing STAT activity as a therapeutic strategy. Cancers (Basel). 2019;11(11). https://doi.org/10.3390/cancers11111716.

49.

Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia. 2008;13(1):93–103. https://doi.org/10.1007/s10911-008-9062-z.CrossRefPubMed

50.

Ahonen TJ, Xie J, LeBaron MJ, Zhu J, Nurmi M, Alanen K, Rui H, Nevalainen MT. Inhibition of transcription factor Stat5 induces cell death of human prostate cancer cells. J Biol Chem. 2003;278(29):27287–92. https://doi.org/10.1074/jbc.M304307200.CrossRefPubMed

51.

Wu P, Wu D, Zhao L, Huang L, Shen G, Huang J, Chai Y. Prognostic role of STAT3 in solid tumors: a systematic review and meta-analysis. Oncotarget. 2016;7(15):19863–83. https://doi.org/10.18632/oncotarget.7887.CrossRefPubMedPubMedCentral

52.

Carpenter RL, Lo HW. STAT3 target genes relevant to human cancers. Cancers (Basel). 2014;6(2):897–925. https://doi.org/10.3390/cancers6020897.CrossRefPubMed

53.

Huang LL, Rao W. SiRNA interfering STAT3 enhances DDP sensitivity in cervical cancer cells. Eur Rev Med Pharmacol Sci. 2018;22(13):4098–106. https://doi.org/10.26355/eurrev_201807_15401.CrossRefPubMed

54.

Sobti RC, Singh N, Hussain S, Suri V, Bharadwaj M, Das BC. Deregulation of STAT-5 isoforms in the development of HPV-mediated cervical carcinogenesis. J Recept Signal Transduct Res. 2010;30(3):178–88. https://doi.org/10.3109/10799891003786218.CrossRefPubMed

Title: Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer
Authors: Chunnian Zhang
Liqin Gu
Juan Xiao
Feng Jin
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Cervical Cancer
Cervical Cancer
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-11163-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Clinical significance of histopathological features of paired recurrent gliomas: a cohort study from a single cancer center

MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and TPM4

Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study

Intra-abdominal infection after tumor surgery: tigecycline combined with β-lactam antibiotics versus tigecycline alone

Clinical trials in cancer screening, prevention and early diagnosis (SPED): a systematic mapping review

Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer